文献速递乳腺癌支持与姑息治疗

地舒单抗辅助治疗早期乳腺癌的III期随机对照试验(D-CARE)

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-12-02

D-CARE是一项国际多中心双盲随机安慰剂对照III期试验,纳入4509例II-III期乳腺癌女性,评估地舒单抗联合标准辅助/新辅助治疗是否改善无骨转移生存。

要点

  • 地舒单抗联合标准治疗未显著改善早期乳腺癌无骨转移生存。
  • 地舒单抗组颌骨坏死发生率5%,安慰剂组<1%。
  • 地舒单抗组治疗相关低钙血症发生率7%,安慰剂组4%。

核心结论

  • 尽管临床前证据提示RANKL抑制可能延缓骨转移或疾病复发,但本研究显示地舒单抗未改善高危早期乳腺癌女性的疾病相关结局。

研究设计与样本

  • 国际双盲随机安慰剂对照III期试验,从39个国家389个中心纳入4509例组织学确诊的II或III期乳腺癌女性,ECOG体能状态0或1。
  • 患者按1:1随机接受地舒单抗120 mg或匹配安慰剂皮下注射,起始于新辅助或辅助化疗,每3-4周一次约6个月,之后每12周一次,总疗程5年。
  • 主要终点为无骨转移生存的复合终点,分析数据截止日期为2017年8月31日。

主要发现

  • 最常见≥3级治疗中出现的不良事件:中性粒细胞减少(地舒单抗340例[15%] vs 安慰剂328例[15%])、发热性中性粒细胞减少(112例[5%] vs 142例[6%])、白细胞减少(62例[3%] vs 61例[3%])。
  • 经阳性 adjudication 的颌骨坏死在地舒单抗组为122/2241例(5%),安慰剂组为4/2218例(<1%);治疗中出现低钙血症分别为152例(7%)与82例(4%)。
  • 安慰剂组发生2例治疗相关死亡,原因为急性髓系白血病和意识水平下降。

临床怎么用

  • 不推荐在标准辅助/新辅助治疗中常规联合地舒单抗以改善早期乳腺癌疾病相关结局。
  • 使用地舒单抗时需监测颌骨坏死和低钙血症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Denosumab is a fully human monoclonal antibody that binds to, and inhibits, the receptor activator of RANKL (TNFSF11) and might affect breast cancer biology, as shown by preclinical evidence. We aimed to assess whether denosumab combined with standard-of-care adjuvant or neoadjuvant systemic therapy and locoregional treatments would increase bone metastasis-free survival in women with breast cancer. METHOD: In this international, double-blind, randomised, placebo-controlled, phase 3 study (D-CARE), patients were recruited from 389 centres in 39 countries. We enrolled women (aged ≥ 18 years) with histologically confirmed stage II or III breast cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1. On eligibility confirmation, investigators at each site telephoned an interactive voice response system to centrally randomly assign patients (1:1) based on a fixed stratified permuted block randomisation list (block size 4) to receive either denosumab (120 mg) or matching placebo subcutaneously every 3-4 weeks, starting with neoadjuvant or adjuvant chemotherapy, for about 6 months and then every 12 weeks for a total duration of 5 years. Stratification factors were breast cancer therapy, lymph node status, hormone receptor and HER2 status, age, and geographical region. The primary endpoint was the composite endpoint of bone metastasis-free survival. This trial is registered with ClinicalTrials.gov, NCT01077154. FINDINGS: Between June 2, 2010, and Aug 24, 2012, 4509 women were randomly assigned to receive denosumab (n=2256) or placebo (n=2253) and included in the intention-to-treat analysis. The primary analysis of the study was done when all patients had the opportunity to complete 5 years of follow-up with an analysis data cutoff date of Aug 31, 2017. The primary endpoint of bone metastasis-free survival was not significantly different between the groups (median not reached in either group; hazard ratio 0·97, 95% CI 0·82-1·14; p=0·70). The most common grade 3 or worse treatment-emergent adverse events, reported in patients who had at least one dose of the investigational product (2241 patients with denosumab vs 2218 patients with placebo), were neutropenia (340 [15%] vs 328 [15%]), febrile neutropenia (112 [5%] vs 142 [6%]), and leucopenia (62 [3%] vs 61 [3%]). Positively adjudicated osteonecrosis of the jaw occurred in 122 (5%) of 2241 patients treated with denosumab versus four (<1%) of 2218 patients treated with placebo; treatment-emergent hypocalcaemia occurred in 152 (7%) versus 82 (4%). Two treatment-related deaths occurred in the placebo group due to acute myeloid leukaemia and depressed level of consciousness. INTERPRETATION: Despite preclinical evidence suggesting RANKL inhibition might delay bone metastasis or disease recurrence in patients with early-stage breast cancer, in this study, denosumab did not improve disease-related outcomes for women with high-risk early breast cancer. FUNDING: Amgen.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2019. PMID: 31806543. doi:10.1016/S1470-2045(19)30687-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。